Synairgen announces global strategic partnership with Ashfield Engage PR Newswire SOUTHAMPTON, United Kingdom, Jan. 6, 2022 SOUTHAMPTON, United Kingdom , Jan. 6, 2022 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, today announces a partnership with global experts in strategic...